{
  "ticker": "ACR",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02974267",
  "id": "02974267",
  "pages": 7,
  "price_sensitive": true,
  "date": "20250730",
  "time": "0903",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250730/pdf/06m99817pftwfm.pdf",
  "summary": "### **Quarterly Report (Appendix 4C) \u2013 Key Material Highlights**  \n\n#### **Operational Updates**  \n- **New product launches**: Dapsone 7.5% Gel (May 2025), joining Dapsone 5% Gel (April 2024) and Nitroglycerin 0.4% Ointment (December 2024).  \n- **Revenue catalyst**: June-quarter sales growth driving higher profit share income (receivable in August).  \n- **Market traction**: Nitroglycerin Ointment sales volumes up **300% QoQ** with strong market share.  \n\n#### **Financial Highlights**  \n- **Cash balance (30 June 2025)**: **$0.863 million** (down from $1.036M last quarter).  \n- **Net operating cash outflow**: **($1.832 million)** (R&D: $0.537M, staff costs: $1.029M).  \n- **Funding**:  \n  - Received **$1.73M (April)** and **$0.46M (July)** via short-term R&D tax incentive-backed loans (16% interest rate).  \n  - **Estimated funding runway**: **0.5 quarters** (management expects improved receipts in September quarter).  \n\n#### **Liquidity Risk Highlight**  \n- **Low cash runway**: Only **~0.5 quarters** of funding left\u2014monitor August profit share receipts and RDTI rebate collection.  \n\n**No other material information identified.**",
  "usage": {
    "prompt_tokens": 4401,
    "completion_tokens": 315,
    "total_tokens": 4716,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-29T23:22:48.873511"
}